<DOC>
	<DOCNO>NCT01831661</DOCNO>
	<brief_summary>The study randomize , open label , two-treatment , two-period , two-sequence , single dose , crossover , oral bioequivalence study normal , healthy adult human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition</brief_title>
	<detailed_description>Objective study compare evaluate single-dose oral bioavailability Metformin Hydrochloride Extended-Release Tablets USP 750 mg Ipca Laboratories Ltd , India GLUCOPHAGEÂ®XR ( Metformin HCl extended-release tablet ) 750 mg Bristol-Myers Squibb Company , USA normal , healthy , adult , human subject fast condition . Total duration study 17 day day admission first period till end second period . Upon enter study , subject house clinical facility Veeda Clinical Research Pvt . Ltd. ensure 10 hour overnight fast dose continue housed facility till 36.00 hour post-dose blood sample collection two period . A gap 14 day keep wash consecutive dosing period .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Subjects age 18 45 year ( include ) . 2 . Subjects ' weight within normal range accord normal value Body Mass Index ( 18.5 24.9 kg/m2 ) ( include ) minimum 50 kg weight . 3 . Subjects normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable normal range . 4 . Subjects clinically acceptable 12lead electrocardiogram ( ECG ) . 5 . Subjects clinically acceptable chest XRay ( PA view ) . 6 . Subjects negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 7 . Subjects negative alcohol breathe test . 8 . Subjects willing adhere protocol requirement provide write informed consent . 9 . Subjects negative BetahCG Pregnancy test ( female subject ) . 10 . For Female Subjects : 1 ) Female child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence , 2 ) Postmenopausal least 1 year , le 1 year , follow acceptable contraceptive measure mention 3 ) Surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) . 1 . Hypersensitivity Metformin excipients related class drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . Any treatment could bring induction inhibition hepatic microsomal enzyme system within 1 month study start 4 . History Presence significant alcoholism drug abuse . 5 . History presence significant asthma , urticaria allergic reaction . 6 . History presence significant gastric and/or duodenal ulceration . 7 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumor . 8 . History presence cancer . 9 . History presence significant easy bruise bleeding . 10 . History presence significant recent trauma . 11 . Subjects abnormal diet ( whatever reason ) four week precede study . 12 . Difficulty donate blood . 13 . Difficulty swallow solid like tablet capsule . 14 . Use prescribed OTC medication last two week prior dose period 01 . 15 . Consumption grapefruit juice , xanthinecontaining product , tobacco containing product alcohol within 48 hour prior dose . 16 . Major illness 3 month screen . 17 . Participation drug research study within past 3 month . 18 . Donation blood past 3 month screen . 19 . Female subject currently breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>